A 62-year-old woman undergoes staging surgery for endometrial cancer. Pathology shows a Grade 3 serous adenocarcinoma with myometrial invasion limited to the inner half of the myometrium. No extrauterine disease is identified. Regarding adjuvant therapy for this patient, all of the following statements are correct EXCEPT:

Explanation

## High-Risk Endometrial Cancer: Serous Adenocarcinoma — Adjuvant Therapy **Key Point:** Grade 3 serous adenocarcinoma is classified as **high-risk endometrial cancer** regardless of myometrial invasion depth. The PORTEC-3 trial is the landmark study guiding adjuvant therapy in this setting. ### Risk Stratification for Serous Adenocarcinoma **High-Yield:** Serous adenocarcinoma is inherently high-risk because: - It has aggressive biological behavior with high propensity for lymph node and peritoneal spread - It is NOT stage-dependent — even Stage IA serous carcinoma is considered high-risk and warrants systemic chemotherapy - Myometrial invasion depth modifies prognosis but does **not** override the mandate for chemotherapy in serous histology | Feature | Implication | | --- | --- | | **Grade 3 histology** | High-risk | | **Serous adenocarcinoma** | High-risk (independent of grade/stage) | | **Clear cell adenocarcinoma** | High-risk (independent of grade/stage) | | **Myometrial invasion** | Modifies risk intensity but does NOT override serous histology mandate | ### Why Statement B Is Incorrect (The EXCEPT Answer) **Clinical Pearl:** The **PORTEC-3 trial** (de Boer et al., *Lancet Oncology*, 2018 update) demonstrated that combined chemoradiotherapy (carboplatin-paclitaxel + pelvic radiotherapy) improves **failure-free survival (FFS) and progression-free survival** in high-risk endometrial cancer compared to radiotherapy alone. However, the trial did **NOT** demonstrate a statistically significant improvement in **overall survival (OS)** compared to radiotherapy alone in the primary analysis. Therefore, the statement that "combined chemotherapy and radiotherapy improves overall survival compared to radiotherapy alone" is **incorrect** — it improves progression-free/failure-free survival, not overall survival. ### Why the Other Statements Are Correct - **Option A:** Carboplatin + paclitaxel IS indicated for serous adenocarcinoma regardless of myometrial invasion depth — serous histology alone mandates chemotherapy even in Stage IA disease (NCCN guidelines). - **Option C:** Serous histology IS an independent risk factor for recurrence and warrants chemotherapy — well-established in gynecologic oncology literature (Berek & Novak's Gynecology). - **Option D:** Pelvic radiotherapy alone IS insufficient for Grade 3 serous carcinoma — monotherapy with radiotherapy does not adequately address the systemic spread potential of serous histology; combined modality therapy is recommended (NCCN, ESMO guidelines). **Reference:** de Boer SM et al. "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial." *Lancet Oncology*, 2018. Berek & Novak's Gynecology, 16th edition.